# Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

> **NCT02214953** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 17 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 11634 ER formulation A
- **DRUG:** BI 11634 ER formulation B
- **DRUG:** BI 11634 ER formulation M
- **DRUG:** BI 11634 ER formulation C
- **DRUG:** BI 11634 IR tablet

## Key facts

- **NCT ID:** NCT02214953
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2007-12
- **Final completion:** —
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02214953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02214953, "Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02214953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*